Two-day oral administration of ivabradine did not significantly reduce capsaicin-induced spontaneous pain compared to placebo in healthy volunteers.
RCT (n=20)
Double-blind
Computer randomization
No
Does ivabradine reduce capsaicin-induced spontaneous pain in healthy volunteers?
Short-term administration of the HCN channel blocker ivabradine did not reduce capsaicin-induced spontaneous pain but significantly reduced secondary dynamic mechanical allodynia in healthy volunteers.
Tasa de eventos absoluta: 33.5% vs 34.4%
valor p: p=0.7479
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels have been focused on as a potential therapeutic target for inflammatory and neuropathic pain in rodent models. However, roles of HCN channels in human pain states have been scarcely investigated. We evaluated analgesic effects of 2-day administration of ivabradine, the only clinically available HCN channel blocker, on a capsaicin pain model in a randomized, double-blinded, placebo-controlled, crossover study. Twenty healthy adult subjects (18 males, 2 females) received ivabradine (5-7.5 mg) or a placebo 3 times in 2 days. Then capsaicin (0.5%) was topically applied on the volar forearm for 30 min. The primary outcome was capsaicin-induced spontaneous pain. The secondary outcomes included heat-pain threshold (HPT), flare size, and areas of secondary punctate mechanical hyperalgesia (PMH) and secondary dynamic mechanical allodynia (DMA). There was no significant difference in spontaneous pain (p = 0.7479), HPT (p = 0.7501), area of PMH (p = 0.1052) or flare size (p = 0.5650) at 30 min after capsaicin application between the groups. In contrast, the area of DMA in the ivabradine group was significantly smaller (p < 0.001) than that in the placebo group. HCN channels may be differentially involved in the various pain signal transmission pathways in humans.
Tanaka et al. (Fri,) conducted a rct in Capsaicin-induced pain model (n=20). Ivabradine vs. Placebo was evaluated on Capsaicin-induced spontaneous pain at 30 min (VAS score) (95% CI -6.1 to 4.3, p=0.7479). Two-day oral administration of ivabradine did not significantly reduce capsaicin-induced spontaneous pain compared to placebo in healthy volunteers.